Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 18 entries
Sorted by: Best Match Show Resources per page
Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis.

American health & drug benefits

Punekar R, Choi J, Boklage S, Iglesias-Rodriguez M, Nola K.
PMID: 32030116
Am Health Drug Benefits. 2019 Dec;12(8):400-409.

BACKGROUND: The treatment of rheumatoid arthritis is based on the use of disease-modifying antirheumatic drugs (DMARDs). Tocilizumab can be used as monotherapy or in combination with conventional synthetic DMARDs for the treatment of moderate-to-severe active rheumatoid arthritis. Subcutaneous (SC)...

Cite
Punekar R, Choi J, Boklage S, et al. Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis. Am Health Drug Benefits. 2019;12(8):400-409
Punekar, R., Choi, J., Boklage, S., Iglesias-Rodriguez, M., & Nola, K. (2019). Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis. American health & drug benefits, 12(8), 400-409.
Punekar, Rajeshwari, et al. "Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis." American health & drug benefits vol. 12,8 (2019): 400-409.
Punekar R, Choi J, Boklage S, Iglesias-Rodriguez M, Nola K. Real-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis. Am Health Drug Benefits. 2019 Dec;12(8):400-409. PMID: 32030116; PMCID: PMC6986546.
Copy Download .nbib Format: NLM
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians.

Rheumatology and therapy

Sullivan E, Kershaw J, Blackburn S, Choi J, Curtis JR, Boklage S.
PMID: 32318979
Rheumatol Ther. 2020 Jun;7(2):383-400. doi: 10.1007/s40744-020-00203-w. Epub 2020 Apr 21.

INTRODUCTION: Some patients with rheumatoid arthritis (RA) using tumor necrosis factor inhibitors (TNFi) experience inefficacy or lack of tolerability and hence switch to another TNFi (cycling) or to a therapy with another mode of action (switching). This study examined...

Cite
Sullivan E, Kershaw J, Blackburn S, et al. Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians. Rheumatol Ther. 2020;7(2):383-400doi: 10.1007/s40744-020-00203-w.
Sullivan, E., Kershaw, J., Blackburn, S., Choi, J., Curtis, J. R., & Boklage, S. (2020). Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians. Rheumatology and therapy, 7(2), 383-400. https://doi.org/10.1007/s40744-020-00203-w
Sullivan, Emma, et al. "Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians." Rheumatology and therapy vol. 7,2 (2020): 383-400. doi: https://doi.org/10.1007/s40744-020-00203-w
Sullivan E, Kershaw J, Blackburn S, Choi J, Curtis JR, Boklage S. Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians. Rheumatol Ther. 2020 Jun;7(2):383-400. doi: 10.1007/s40744-020-00203-w. Epub 2020 Apr 21. PMID: 32318979; PMCID: PMC7211222.
Copy Download .nbib Format: NLM
Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng .

Annals of the rheumatic diseases

Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM.
PMID: 33177102
Ann Rheum Dis. 2020 Nov 11; doi: 10.1136/annrheumdis-2020-218907. Epub 2020 Nov 11.

No abstract available.

Cite
Pappas DA, St John G, Etzel CJ, et al. Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218907.
Pappas, D. A., St John, G., Etzel, C. J., Fiore, S., Blachley, T., Kimura, T., Punekar, R., Emeanuru, K., Choi, J., Boklage, S., & Kremer, J. M. (2020). Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218907
Pappas, Dimitrios A, et al. "Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218907
Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng . Ann Rheum Dis. 2020 Nov 11; doi: 10.1136/annrheumdis-2020-218907. Epub 2020 Nov 11. PMID: 33177102.
Copy Download .nbib Format: NLM
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan.

Rheumatology and therapy

Sullivan E, Kershaw J, Blackburn S, Mahajan P, Boklage SH.
PMID: 32440826
Rheumatol Ther. 2020 Sep;7(3):517-535. doi: 10.1007/s40744-020-00211-w. Epub 2020 May 21.

INTRODUCTION: Tumor necrosis factor inhibitors (TNFi) are commonly used as first-line therapy (biologic disease-modifying antirheumatic drug [bDMARD] and targeted synthetic DMARD [tsDMARD]: defined as targeted therapy) for patients with moderate-to-severe rheumatoid arthritis (RA), usually combined with conventional synthetic DMARDs...

Cite
Sullivan E, Kershaw J, Blackburn S, et al. Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan. Rheumatol Ther. 2020;7(3):517-535doi: 10.1007/s40744-020-00211-w.
Sullivan, E., Kershaw, J., Blackburn, S., Mahajan, P., & Boklage, S. H. (2020). Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan. Rheumatology and therapy, 7(3), 517-535. https://doi.org/10.1007/s40744-020-00211-w
Sullivan, Emma, et al. "Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan." Rheumatology and therapy vol. 7,3 (2020): 517-535. doi: https://doi.org/10.1007/s40744-020-00211-w
Sullivan E, Kershaw J, Blackburn S, Mahajan P, Boklage SH. Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan. Rheumatol Ther. 2020 Sep;7(3):517-535. doi: 10.1007/s40744-020-00211-w. Epub 2020 May 21. PMID: 32440826; PMCID: PMC7410899.
Copy Download .nbib Format: NLM
Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence.

Patient preference and adherence

Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T.
PMID: 27354772
Patient Prefer Adherence. 2016 Jun 08;10:1025-35. doi: 10.2147/PPA.S102760. eCollection 2016.

BACKGROUND: The treatment failure rate for Helicobacter pylori eradication therapy is ~20% due to poor patient compliance and increased antibiotic resistance. This analysis assessed the cost-effectiveness of universal post-treatment testing to confirm eradication of H. pylori infection in adults.METHODS:...

Cite
Boklage SH, Mangel AW, Ramamohan V, et al. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient Prefer Adherence. 2016;10:1025-35doi: 10.2147/PPA.S102760.
Boklage, S. H., Mangel, A. W., Ramamohan, V., Mladsi, D., & Wang, T. (2016). Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient preference and adherence, 101025-35. https://doi.org/10.2147/PPA.S102760
Boklage, Susan H, et al. "Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence." Patient preference and adherence vol. 10 (2016): 1025-35. doi: https://doi.org/10.2147/PPA.S102760
Boklage SH, Mangel AW, Ramamohan V, Mladsi D, Wang T. Cost-effectiveness analysis of universal noninvasive testing for post-treatment confirmation of Helicobacter pylori eradication and the impact of patient adherence. Patient Prefer Adherence. 2016 Jun 08;10:1025-35. doi: 10.2147/PPA.S102760. eCollection 2016. PMID: 27354772; PMCID: PMC4908940.
Copy Download .nbib Format: NLM
Group-Based Trajectory Models to Identify Sociodemographic and Clinical Predictors of Adherence Patterns to Statin Therapy Among Older Adults.

American health & drug benefits

Vadhariya A, Fleming ML, Johnson ML, Essien EJ, Serna O, Esse T, Choi J, Boklage SH, Abughosh SM.
PMID: 31428238
Am Health Drug Benefits. 2019 Jun-Jul;12(4):202-211.

BACKGROUND: The benefits of statins in the prevention of primary and secondary atherosclerotic cardiovascular (CV) disease events have been well documented. Suboptimal adherence is a persistent problem associated with increased CV events and increased healthcare utilization. Proportion of days...

Cite
Vadhariya A, Fleming ML, Johnson ML, et al. Group-Based Trajectory Models to Identify Sociodemographic and Clinical Predictors of Adherence Patterns to Statin Therapy Among Older Adults. Am Health Drug Benefits. 2019;12(4):202-211
Vadhariya, A., Fleming, M. L., Johnson, M. L., Essien, E. J., Serna, O., Esse, T., Choi, J., Boklage, S. H., & Abughosh, S. M. (2019). Group-Based Trajectory Models to Identify Sociodemographic and Clinical Predictors of Adherence Patterns to Statin Therapy Among Older Adults. American health & drug benefits, 12(4), 202-211.
Vadhariya, Aisha, et al. "Group-Based Trajectory Models to Identify Sociodemographic and Clinical Predictors of Adherence Patterns to Statin Therapy Among Older Adults." American health & drug benefits vol. 12,4 (2019): 202-211.
Vadhariya A, Fleming ML, Johnson ML, Essien EJ, Serna O, Esse T, Choi J, Boklage SH, Abughosh SM. Group-Based Trajectory Models to Identify Sociodemographic and Clinical Predictors of Adherence Patterns to Statin Therapy Among Older Adults. Am Health Drug Benefits. 2019 Jun-Jul;12(4):202-211. PMID: 31428238; PMCID: PMC6684050.
Copy Download .nbib Format: NLM
Identifying factors that impact general dentists' referrals to orthodontists.

American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics

Lee DS, Sulkowski T, Bocklage C, Frazier-Bowers SA, Wiesen C, Mihas P, Jacox LA.
PMID: 34538711
Am J Orthod Dentofacial Orthop. 2021 Sep 16; doi: 10.1016/j.ajodo.2021.07.010. Epub 2021 Sep 16.

INTRODUCTION: Referrals from general dentists are a significant source of orthodontic patients, but our knowledge of factors guiding referral decisions predates recent marketplace trends of direct-to-consumer products and broad digitization. To provide orthodontists with current, nationwide data on referral...

Cite
Lee DS, Sulkowski T, Bocklage C, et al. Identifying factors that impact general dentists' referrals to orthodontists. Am J Orthod Dentofacial Orthop. 2021;doi: 10.1016/j.ajodo.2021.07.010.
Lee, D. S., Sulkowski, T., Bocklage, C., Frazier-Bowers, S. A., Wiesen, C., Mihas, P., & Jacox, L. A. (2021). Identifying factors that impact general dentists' referrals to orthodontists. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics, . https://doi.org/10.1016/j.ajodo.2021.07.010
Lee, Daniel S, et al. "Identifying factors that impact general dentists' referrals to orthodontists." American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics vol. (2021). doi: https://doi.org/10.1016/j.ajodo.2021.07.010
Lee DS, Sulkowski T, Bocklage C, Frazier-Bowers SA, Wiesen C, Mihas P, Jacox LA. Identifying factors that impact general dentists' referrals to orthodontists. Am J Orthod Dentofacial Orthop. 2021 Sep 16; doi: 10.1016/j.ajodo.2021.07.010. Epub 2021 Sep 16. PMID: 34538711.
Copy Download .nbib Format: NLM
Orthognathic speech pathology: impacts of Class III malocclusion on speech.

European journal of orthodontics

Lathrop-Marshall H, Keyser MMB, Jhingree S, Giduz N, Bocklage C, Couldwell S, Edwards H, Glesener T, Moss K, Frazier-Bowers S, Phillips C, Turvey T, Blakey G, White R, Mielke J, Zajac D, Jacox LA.
PMID: 34562076
Eur J Orthod. 2021 Sep 25; doi: 10.1093/ejo/cjab067. Epub 2021 Sep 25.

INTRODUCTION: Patients with dentofacial disharmonies (DFDs) seek orthodontic care and orthognathic surgery to address issues with mastication, esthetics, and speech. Speech distortions are seen 18 times more frequently in Class III DFD patients than the general population, with unclear...

Cite
Lathrop-Marshall H, Keyser MMB, Jhingree S, et al. Orthognathic speech pathology: impacts of Class III malocclusion on speech. Eur J Orthod. 2021;doi: 10.1093/ejo/cjab067.
Lathrop-Marshall, H., Keyser, M. M. B., Jhingree, S., Giduz, N., Bocklage, C., Couldwell, S., Edwards, H., Glesener, T., Moss, K., Frazier-Bowers, S., Phillips, C., Turvey, T., Blakey, G., White, R., Mielke, J., Zajac, D., & Jacox, L. A. (2021). Orthognathic speech pathology: impacts of Class III malocclusion on speech. European journal of orthodontics, . https://doi.org/10.1093/ejo/cjab067
Lathrop-Marshall, Hillary, et al. "Orthognathic speech pathology: impacts of Class III malocclusion on speech." European journal of orthodontics vol. (2021). doi: https://doi.org/10.1093/ejo/cjab067
Lathrop-Marshall H, Keyser MMB, Jhingree S, Giduz N, Bocklage C, Couldwell S, Edwards H, Glesener T, Moss K, Frazier-Bowers S, Phillips C, Turvey T, Blakey G, White R, Mielke J, Zajac D, Jacox LA. Orthognathic speech pathology: impacts of Class III malocclusion on speech. Eur J Orthod. 2021 Sep 25; doi: 10.1093/ejo/cjab067. Epub 2021 Sep 25. PMID: 34562076.
Copy Download .nbib Format: NLM
[Risk communication in the containment of the COVID-19 pandemic: challenges and promising approaches].

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz

Loss J, Boklage E, Jordan S, Jenny MA, Weishaar H, El Bcheraoui C.
PMID: 33564896
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 Mar;64(3):294-303. doi: 10.1007/s00103-021-03283-3. Epub 2021 Feb 09.

Risk communication plays a central role in public health emergencies: it must enable informed decisions, promote protective or life-sustaining behaviour, and maintain trust in public institutions. In addition, uncertainties in knowledge must be named transparently; irrational fears and rumours...

Cite
Loss J, Boklage E, Jordan S, et al. Risikokommunikation bei der Eindämmung der COVID-19-Pandemie: Herausforderungen und Erfolg versprechende Ansätze. [Risk communication in the containment of the COVID-19 pandemic: challenges and promising approaches]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021;64(3):294-303doi: 10.1007/s00103-021-03283-3.
Loss, J., Boklage, E., Jordan, S., Jenny, M. A., Weishaar, H., & El Bcheraoui, C. (2021). Risikokommunikation bei der Eindämmung der COVID-19-Pandemie: Herausforderungen und Erfolg versprechende Ansätze. [Risk communication in the containment of the COVID-19 pandemic: challenges and promising approaches]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 64(3), 294-303. https://doi.org/10.1007/s00103-021-03283-3
Loss, Julika, et al. "Risikokommunikation bei der Eindämmung der COVID-19-Pandemie: Herausforderungen und Erfolg versprechende Ansätze." [Risk communication in the containment of the COVID-19 pandemic: challenges and promising approaches]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz vol. 64,3 (2021): 294-303. doi: https://doi.org/10.1007/s00103-021-03283-3
Loss J, Boklage E, Jordan S, Jenny MA, Weishaar H, El Bcheraoui C. Risikokommunikation bei der Eindämmung der COVID-19-Pandemie: Herausforderungen und Erfolg versprechende Ansätze. [Risk communication in the containment of the COVID-19 pandemic: challenges and promising approaches]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2021 Mar;64(3):294-303. doi: 10.1007/s00103-021-03283-3. Epub 2021 Feb 09. German. PMID: 33564896; PMCID: PMC7872109.
Copy Download .nbib Format: NLM
Understanding technology adoption by orthodontists: A quantitative study.

American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics

Jacox LA, Bocklage C, Edwards T, Mihas P, Lin FC, Ko CC.
PMID: 34690040
Am J Orthod Dentofacial Orthop. 2021 Oct 21; doi: 10.1016/j.ajodo.2020.08.024. Epub 2021 Oct 21.

INTRODUCTION: Digital scanning, treatment planning, 3-dimensional imaging, and printing are changing the practice of orthodontics. These tools are adopted with the hope that treatment becomes more predictable, efficient, and effective while reducing adverse outcomes. Digital tools are impacting care,...

Cite
Jacox LA, Bocklage C, Edwards T, et al. Understanding technology adoption by orthodontists: A quantitative study. Am J Orthod Dentofacial Orthop. 2021;doi: 10.1016/j.ajodo.2020.08.024.
Jacox, L. A., Bocklage, C., Edwards, T., Mihas, P., Lin, F. C., & Ko, C. C. (2021). Understanding technology adoption by orthodontists: A quantitative study. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics, . https://doi.org/10.1016/j.ajodo.2020.08.024
Jacox, Laura Anne, et al. "Understanding technology adoption by orthodontists: A quantitative study." American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics vol. (2021). doi: https://doi.org/10.1016/j.ajodo.2020.08.024
Jacox LA, Bocklage C, Edwards T, Mihas P, Lin FC, Ko CC. Understanding technology adoption by orthodontists: A quantitative study. Am J Orthod Dentofacial Orthop. 2021 Oct 21; doi: 10.1016/j.ajodo.2020.08.024. Epub 2021 Oct 21. PMID: 34690040.
Copy Download .nbib Format: NLM
Self-development.

Journal of continuing education in nursing

Boklage MG.
PMID: 5002054
J Contin Educ Nurs. 1971 Nov-Dec;2(6):14-20.

No abstract available.

Cite
Boklage MG. Self-development. J Contin Educ Nurs. 1971;2(6):14-20
Boklage, M. G. (1971). Self-development. Journal of continuing education in nursing, 2(6), 14-20.
Boklage, M G. "Self-development." Journal of continuing education in nursing vol. 2,6 (1971): 14-20.
Boklage MG. Self-development. J Contin Educ Nurs. 1971 Nov-Dec;2(6):14-20. PMID: 5002054.
Copy Download .nbib Format: NLM
Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies.

ClinicoEconomics and outcomes research : CEOR

Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, Chen CI.
PMID: 30532571
Clinicoecon Outcomes Res. 2018 Nov 16;10:805-819. doi: 10.2147/CEOR.S163829. eCollection 2018.

OBJECTIVE: To estimate the 5-year budget impact (BI) on a US health plan of introducing sarilumab - a human immunoglobulin G1 anti-IL-6 receptor α monoclonal antibody - as combination treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or monotherapy...

Cite
Ferrufino CP, Munakata J, Wei W, et al. Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. Clinicoecon Outcomes Res. 2018;10:805-819doi: 10.2147/CEOR.S163829.
Ferrufino, C. P., Munakata, J., Wei, W., Proudfoot, C., Kuznik, A., Boklage, S. H., & Chen, C. I. (2018). Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. ClinicoEconomics and outcomes research : CEOR, 10805-819. https://doi.org/10.2147/CEOR.S163829
Ferrufino, Cheryl P, et al. "Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies." ClinicoEconomics and outcomes research : CEOR vol. 10 (2018): 805-819. doi: https://doi.org/10.2147/CEOR.S163829
Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, Chen CI. Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. Clinicoecon Outcomes Res. 2018 Nov 16;10:805-819. doi: 10.2147/CEOR.S163829. eCollection 2018. PMID: 30532571; PMCID: PMC6247948.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 18 entries